NCT05296447
Long-Term Follow-Up Study of RGX-314 Administered in the Suprachoroidal Space for Participants With Diabetic Retinopathy
Enrolling by Invitation
Not specifiedAll AgesObservationalAbbVie
~100 participants
Updated 2025-06-18 on ClinicalTrials.gov
What's tested:No Intervention
At a glance
Recruiting sites
0 of 19 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
To evaluate the long-term safety of RGX-314
Measured over 5 years inclusive of the parent study
Conditions
Where it's being run
19 sites across 12 statesCalifornia7
Texas2
Arizona1
Illinois1
Maryland1
Massachusetts1
Nevada1
New Jersey1
Who to contact
This trial hasn't published a contact. View it on ClinicalTrials.gov
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Eligibility criteria
Inclusion
Must provide written, signed informed consent for this study
Must have been enrolled in a previous clinical study of RGX-314 for the treatment of DR without CI-DME and must have received an SCS injection of RGX-314 in that study
Must be willing and able to comply with all study procedures
Exclusion
None
What this trial measures
- To evaluate the long-term safety of RGX-3145 years inclusive of the parent study
Incidence of overall and ocular adverse events, serious adverse events, and all adverse events of special interest